Precigen, Inc. (PGEN) P/E Ratio History
Premium ValuationTrading at 77.2x vs 5Y avg 56.9x · 80th percentile · Premium to historical baseline · Data 2022–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Precigen, Inc. (PGEN) trades at a price-to-earnings ratio of 77.2x, with a stock price of $4.47 and trailing twelve-month earnings per share of $0.06.
The current P/E is 36% above its 5-year average of 56.9x. Over the past five years, PGEN's P/E has ranged from a low of 8.0x to a high of 223.5x, placing the current valuation at the 80th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, PGEN trades at a 214% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, PGEN commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PGEN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PGEN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PGEN P/E vs Peers
Viral Gene Therapy peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $298M | 21.2Lowest | - | +100% | |
| $32B | 36.7 | 8.67Best | +171%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PGEN Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $8.56 | $0.04 | 223.5x | +293% |
| FY2023 Q2 | Jun 30 2023 | $1.15 | $0.14 | 8.0x | -86% |
| FY2023 Q1 | Mar 31 2023 | $1.06 | $0.10 | 11.0x | -81% |
| FY2022 Q4 | Dec 31 2022 | $1.52 | $0.10 | 15.4x | -73% |
| FY2022 Q3 | Sep 30 2022 | $2.12 | $0.08 | 26.8x | -53% |
Average P/E for displayed period: 56.9x
PGEN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PGEN — Frequently Asked Questions
Quick answers to the most common questions about buying PGEN stock.
What is PGEN's P/E ratio?
Precigen, Inc. (PGEN) trailing twelve-month P/E ratio is 77.2x, based on TTM diluted EPS of $0.06. The 5-year average P/E is 56.9x and the historical range spans 8.0x to 223.5x.
Is PGEN stock overvalued or undervalued?
PGEN trades at 77.2x P/E, above its 5-year average of 56.9x. The 80th percentile ranking within the 8.0x–223.5x historical range indicates a premium to historical valuation.
Is PGEN stock expensive?
Yes, PGEN is expensive relative to its own history. The current P/E of 77.2x is above the 5-year average of 56.9x and also above the Healthcare sector median of 24.6x. The stock sits at the 80th percentile of its 5-year valuation range.
What is PGEN's historical P/E range?
Over the past 5 years, PGEN's P/E ratio has ranged from 8.0x to 223.5x, with a median of 15.4x and an average of 56.9x. The current P/E of 77.2x places the stock at the 80th percentile of this range. Full historical data spans 2022–2026.
How does PGEN's P/E compare to the S&P 500?
PGEN trades at 77.2x P/E versus the S&P 500 median of 21.8x. The 254% premium to the market typically reflects higher expected earnings growth or quality.
How does PGEN's valuation compare to Healthcare peers?
Precigen, Inc. P/E of 77.2x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PGEN's PEG ratio?
PGEN PEG ratio is N/A, based on a P/E of 77.2x and EPS growth of -200.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PGEN's earnings yield?
PGEN earnings yield is 1.30%, the inverse of its 77.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.